[
    [
        {
            "time": "",
            "original_text": "百克生物业绩增长的财技游戏",
            "features": {
                "keywords": [
                    "百克生物",
                    "业绩增长",
                    "财技游戏"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "百克生物业绩增长的财技游戏",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 2,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601)：国内疫苗创新先锋 丰富研发管线步入收获期",
            "features": {
                "keywords": [
                    "康泰生物",
                    "疫苗创新",
                    "研发管线",
                    "收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物(300601)：国内疫苗创新先锋 丰富研发管线步入收获期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "大白马又被杀！3000亿猪茅闪崩跌停，东北药茅大跌",
            "features": {
                "keywords": [
                    "大白马",
                    "猪茅",
                    "闪崩",
                    "跌停",
                    "东北药茅"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "农业"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "大白马又被杀！3000亿猪茅闪崩跌停，东北药茅大跌",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "国金证券：康泰生物（300601.SZ）国内疫苗创新先锋，目标价196元。给予“增持”评级",
            "features": {
                "keywords": [
                    "国金证券",
                    "康泰生物",
                    "疫苗创新",
                    "目标价",
                    "增持"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券：康泰生物（300601.SZ）国内疫苗创新先锋，目标价196元。给予“增持”评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物大跌 连续下跌",
            "features": {
                "keywords": [
                    "康泰生物",
                    "大跌",
                    "连续下跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物大跌 连续下跌",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "国金证券首予康泰生物增持评级：国内疫苗创新先锋，丰富研发管线步入收获期，目标价196元",
            "features": {
                "keywords": [
                    "国金证券",
                    "康泰生物",
                    "疫苗创新",
                    "研发管线",
                    "收获期",
                    "目标价",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券首予康泰生物增持评级：国内疫苗创新先锋，丰富研发管线步入收获期，目标价196元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "疫苗板块逆势下跌，康希诺闪崩大跌9%",
            "features": {
                "keywords": [
                    "疫苗板块",
                    "逆势下跌",
                    "康希诺",
                    "闪崩",
                    "大跌"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "疫苗板块逆势下跌，康希诺闪崩大跌9%",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药行业每周医览药闻：全年业绩确定性强 长期看好院外零售快速发展多元化发展",
            "features": {
                "keywords": [
                    "医药行业",
                    "全年业绩",
                    "确定性",
                    "院外零售",
                    "快速发展",
                    "多元化发展"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业每周医览药闻：全年业绩确定性强 长期看好院外零售快速发展多元化发展",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：20亿可转债提交注册，新增产能或存不能被及时消化风险",
            "features": {
                "keywords": [
                    "康泰生物",
                    "可转债",
                    "新增产能",
                    "风险"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物：20亿可转债提交注册，新增产能或存不能被及时消化风险",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]